František Perlík

František Perlík

Auto-generated profile, based on publicly available information

František Perlík

Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

56Years (1971-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1996 in Journal of Chromatography B: Biomedical Sciences and Applications
Verified
Journal Article
Closed access
MNMilan Nobilis
Milan Nobilis
JPJiří Pastera
Jiří Pastera
PAPavel Anzenbacher
Pavel Anzenbacher
DSDalibor Svoboda
Dalibor Svoboda
JKJiří Kopecký
Jiří Kopecký
FPFrantišek Perlík
František Perlík

1 July 2009 in Journal of Proteome Research
Verified
Journal Article
Closed access
APAndrew Patterson
Andrew Patterson
Ondřej SlanařOndřej Slanař
Ondřej Slanař
KKKristopher W. Krausz
Kristopher W. Krausz
FLFei Li
Fei Li
CHConstance C. Höfer
Constance C. Höfer
JIJeffrey Robert Idle
Jeffrey Robert Idle

15 October 2016 in Acta Pharmaceutica
Verified
Journal Article
Open access
PDF file
MZMiroslav Zeman
Miroslav Zeman
MVMarek Vecka
Marek Vecka
FPFrantišek Perlík
František Perlík
BSBarbora Staňková
Barbora Staňková
RHRobert Hromádka
Robert Hromádka
AŽAleš Žák
Aleš Žák
Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease. Niacin favorably influences all lipoprotein classes, including lipoprotein[a],and belongs to the most potent hypolipidemic drugs for increasing HDL-C. Moreover, niacin causes favorable changes to the qualitative composition of lipoprotein HDL. In addition to its pronounced hypolipidemic action, niacin exerts many other, non-hypolipidemic effects (e.g., antioxidative, anti-inflammatory, antithrombotic), which favorably influence the development and progression of atherosclerosis. These effects are dependent on activation of the specific receptor HCA2. Recent results published by the two large clinical studies, AIM-HIGH and HPS2-THRIVE, have led to the impugnation of niacin’s role in future clinical practice. However, due to several methodological flaws in the AIM-HIGH and HPS2-THRIVE studies, the pleiotropic effects of niacin now deserve thorough evaluation. This review summarizes the present and possible future use of niacin in clinical practice in light of its newly recognized pleiotropic effects.

1 January 2015 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
AŽAleš Žák
Aleš Žák
MZMiroslav Zeman
Miroslav Zeman
MVMarek Vecka
Marek Vecka
FPFrantišek Perlík
František Perlík
RHRóbert Hromádka
Róbert Hromádka
ETEva Tvrzická
Eva Tvrzická
Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with "residual cardiovascular risk", which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy. Recent large randomized clinical studies - AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides) and HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events) - delivered some disappointing results, leading to the conclusion that no further benefit (decreased parameters of cardiovascular risk) is achieved by adding niacin to existing statin therapy in patients with high cardiovascular risk. Moreover, in these studies, several adverse effects of the treatment were observed; therefore, niacin treatment for hypolipidemias is not recommended. In this paper, we analyze the mechanisms underlying the hypolipidemic and antiatherogenic effects of niacin as well as some limitations of the designs of the AIM HIGH and HP2-THRIVE studies. We also provide the possibilities of rational usage of niacin for specific types of dyslipidemias.

1 January 2006 in Folia Biologica
Verified
Journal Article
Open access
PDF file
KPKristina Pechandová
Kristina Pechandová
HBH. Buzková
H. Buzková
Ondřej SlanařOndřej Slanař
Ondřej Slanař
FPF. Perlík
F. Perlík
There exists a marked inter-individual variability of P-glycoprotein expression and activity, which can be of clinical importance due to the large number of drugs that are substrates for the transporter. Previously identified polymorphisms in the MDR1 gene belong to important factors causing this phenomenon. Our aim was to investigate the frequency of major functional SNPs of the MDR1 gene coding for P-glycoprotein in the Czech population. DNA was isolated from whole blood of 189 healthy, young and unrelated subjects (99 females and 90 males, aged from 23 to 28 years). The genotypes of polymorphic positions C3435T, G2677T/A, C1236T and T-76A were determined by PCR-RFLP. Observed allelic frequencies were 56.5%, 46.0%, 0.53%, 44.5% and 37.6% for the alleles 3435T, 2677T, 2677A, 1236T and -76A, respectively. We have found 64 subjects homozygous for 3435T, 42 for 2677T, 40 for 1236T and 31 for -76A alleles. The allelic distribution complies well with Hardy-Weinberg equilibrium. Allelic frequencies of functionally important MDR1 variants are in the Czech population similar to that of other Caucasian populations.

1 July 2009 in Journal of Chromatography B
Verified
Journal Article
Closed access
LCLukáš Chytil
Lukáš Chytil
Martin ŠtíchaMartin Štícha
Martin Štícha
OMOlga Matoušková
Olga Matoušková
FPFrantišek Perlík
František Perlík
Ondřej SlanařOndřej Slanař
Ondřej Slanař